Status:

COMPLETED

A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1

Lead Sponsor:

OPKO Health, Inc.

Conditions:

Type 2 Diabetes

Eligibility:

All Genders

30-60 years

Phase:

PHASE1

Brief Summary

The purpose of the study is to determine whether E1 and G1 are safe and effective in the treatment of type 2 diabetes. Type 2 diabetes is the most common form of diabetes. The disease is characterise...

Detailed Description

In this study, 30 type 2 diabetic patients requiring oral hypoglycemic therapy with Metformin and/or Thiazolidinedione will be randomized. Twenty (20) patients will be randomized to receive active stu...

Eligibility Criteria

Inclusion

  • Informed consent obtained from participants
  • Clinical diagnosis Type 2 diabetes requiring treatment with Metformin and/or TZD and who are otherwise healthy
  • On a stable Metformin and/or TZD regimen for at least 60 days prior to screening
  • Maximum stimulated c-peptide level \> 0.6 nmol/L (1.8 ng/mL)
  • Currently self monitoring blood glucose levels (i.e. daily)
  • No episodes of severe hypoglycemia for 60 days prior to screening
  • Body mass index within the range 25-40 kg/m2
  • Patient cannot live alone during the treatment phase and up to 1 month in follow-up

Exclusion

  • Known of suspected history of significant liver, or other GI disease
  • History of significant cardiovascular disease including stroke, peripheral vascular disease or any related symptoms
  • History of peptic ulcer disease and/or GI bleeding/perforation
  • History of cancer
  • History or presence of proliferative retinopathy, severe non-proliferative retinopathy, macular edema or presence of untreated diabetic eye disease
  • History of treated peripheral or autonomic neuropathy
  • Serum creatine superior or equal to 2.0 mg/dL
  • Non-healed diabetic ulcer
  • History of hypoglycemic unawareness

Key Trial Info

Start Date :

September 1 2005

Trial Type :

INTERVENTIONAL

End Date :

January 1 2007

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT00239187

Start Date

September 1 2005

End Date

January 1 2007

Last Update

October 18 2019

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Profil Institute for Clinical Research Inc.

Chula Vista, California, United States, 91911

2

Clinical Research of West Florida

Clearwater, Florida, United States, 33765-2616

3

Diabetes and Glandular Disease Research Associates

San Antonio, Texas, United States, 78229-4801

A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1 | DecenTrialz